On October 21 global aesthetic manufacturer Teoxane delivered the XPAND conference in London.
250 delegates attended the event, with the agenda covering topics surrounding aesthetics, led by key professionals within the specialty. Leading AI Strategist, Katie King, covered the topic of AI within aesthetics, discussing AI tools for personalising patient interactions and boosting satisfaction. Social media consultant, Andrew Davis, sharing master digital platforms to broaden marketing horizons and personalise your brand online.
The afternoon of XPAND comprised clinical content such as cadaver reviews, anatomy and Anatomy, Technique, Product (ATP) overviews, plus three live demonstrations showcasing ATP treatment fundamentals in each area. Dr Lee Walker explored the ageing process with tailored treatment plans, while Dr Tahera Bhojani Lynch, Dr Raul Cetto and Dr Raj Thethi carried out a review of upper body anatomy with evidence-based treatment tips.
Additionally, Jimmy Faivre, innovation manager for Teoxane, flew in from Geneva to discuss new innovations for the future of the company. Faivre discussed the future use of Mepivacaine to replace lidocaine as an anaesthetic, a new syringe design launch and the evolution of crosslinking technologies.
Alongside the conference, Teoxane has introduced a programme with XPAND to launch in 2025. The strategy is aiming to support clinics across all touch points of their businesses, ranging from marketing and branding, to evidence-based clinical training and consultation planning.
Sandra Fishlock, managing director of Teoxane, commented, “XPAND 2024 represents not just an event, but a community of forward-thinking practitioners and innovators. Our HCP partners’ passion and dedication are what drive the future of aesthetics, and we are honoured to be on this journey with each and every one of the exceptional practitioners that make up our specialty.”
